Pictet Asset Management (Switzerland)’s Coherus Oncology, Inc. Common Stock CHRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | $6.1M | Buy |
1,428,188
+573,930
| +67% | +$2.45M | 0.01% | 730 |
|
|
2023
Q1 | $5.84M | Buy |
854,258
+544,306
| +176% | +$3.72M | 0.01% | 747 |
|
|
2022
Q4 | $2.46M | Buy |
309,952
+78,160
| +34% | +$619K | ﹤0.01% | 890 |
|
|
2022
Q3 | $2.23M | Buy |
231,792
+63,964
| +38% | +$615K | ﹤0.01% | 902 |
|
|
2022
Q2 | $1.22M | Buy |
167,828
+43,889
| +35% | +$318K | ﹤0.01% | 1015 |
|
|
2022
Q1 | $1.6M | Sell |
123,939
-34,636
| -22% | -$447K | ﹤0.01% | 989 |
|
|
2021
Q4 | $2.53M | Hold |
158,575
| – | – | ﹤0.01% | 958 |
|
|
2021
Q3 | $2.55M | Buy |
+158,575
| New | +$2.55M | ﹤0.01% | 951 |
|